- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:patients:mp_duration [07.03.2017] – + unavoidable immune suppressant sallieq | home:patients:mp_duration [07.03.2017] – [Factors influencing length of treatment] sallieq | ||
|---|---|---|---|
| Line 29: | Line 29: | ||
| * **Prior use of immunosuppressants and immunomodulatory medications** – | * **Prior use of immunosuppressants and immunomodulatory medications** – | ||
| * **Fibrosis** – When the immune system fails to kill a pathogen, it encases the diseased tissue in collagen. This process is known as fibrosis. MP patients with fibrosis can expect to be killing pockets of these for a long time, extending the length of the treatment, as the fibrosis remodels. | * **Fibrosis** – When the immune system fails to kill a pathogen, it encases the diseased tissue in collagen. This process is known as fibrosis. MP patients with fibrosis can expect to be killing pockets of these for a long time, extending the length of the treatment, as the fibrosis remodels. | ||
| - | * **Excessive | + | * **Unshielded |
| Line 41: | Line 41: | ||
| //**Greg Blaney, M.D.**//</ | //**Greg Blaney, M.D.**//</ | ||
| + | |||
| + | Some in the latter group have examined their exposure to EMF and discovered that sufficient reduction in exposure resulted in a renewed immune recovery trajectory, often differing in emphasis. | ||
home/patients/mp_duration.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.